© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada. EMD Serono, Inc. One Technology Place, Rockland, MA 02370. Use and access of this site are subject to our Terms & Conditions and Privacy Policy.
Transforming Cancer Care Through Curiosity
Our curiosity drives our goal to unleash the potential of promising approaches in cancer research, driving us to transform cancer care for challenging cancers.
Improving standards of care for challenging cancers through science
EMD Serono is a science-led organization of curious minds dedicated to delivering transformative medicines that can make a difference in the lives of people affected by cancer.
We apply our scientific curiosity to tackling challenging tumor types in key areas—gastrointestinal (GI), genitourinary (GU), and thoracic cancers—where there are unmet needs and where we believe we can drive transformation of patient care.
By relentlessly pursuing potential solutions to even the most complex cancers, we hope to illuminate a path to scientific breakthroughs that impact patient care.
OUR CONGRESS DATA
VIEWPOINTS ON CANCER
OUR PRODUCTS
American Society of Clinical Oncology 2021
POSTERS
Renal Cell Carcinoma- Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
- Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatments (Tx) in JAVELIN Renal 101
- Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study
- Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): longterm follow-up results from JAVELIN Renal 101
- Integrating peripheral biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) vs sunitinib (S) in advanced renal cell carcinoma (aRCC)
- Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line therapy in JAVELIN Bladder 100
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance
ORAL PRESENTATIONS
Cervical CancerAmerican Society of Clinical Oncology 2021
POSTERS
Non-Small Cell Lung CancerAmerican Society of Clinical Oncology 2021
POSTERS
Merkel Cell Carcinoma Head and Neck Cancer Colorectal Cancer DNA Damage RepairCOMPANY NEWS
Read about our latest news in oncology.
